PURPOSE: The appearance of secondary @entity231 constitutes the most common complication of @entity231 surgery since the advent of phacoemulsification. Prevention is today one of the most crucial challenges of research in ophthalmology. We have developed a drug-sustained capsular ring releasing @entity1487 ( @entity1487 ). This system aims to combine mechanical and pharmacological properties with the ability to interfere on the lens epithelial cellular processes of secondary @entity231 . This first article will report on the in vitro evaluation of this system. MATERIALS AND METHOD: Development of a hydrogel that can serve as a mechanical support and as a release of an active agent requires a comparative trial of multiple hydrophobic products providing @entity2003 to the ring and of hydrophilic products providing the ability to release a drug. The choice of @entity1487 as a non-proliferate agent was based on its well-known pharmacological properties and its wide use in ophthalmology. Evaluation comprised adjustment of the adequate copolymer, then of the loading phase, and finally assessment of @entity1487 release. The mechanical characteristics and cytocompatibility of the ring were also assessed. RESULTS: The characteristics of drug release differed depending on the water content and resulting volume of the copolymer. The pharmaceutical and mechanical testing led to selecting the @entity5348 -MMA combination (75:25). However, a burst effect within the first 2 hours was observed in all cases. That limit was eliminated by creating a biodegradable surface coating of Poly Lactid-co-Glycolid (PLG 50:50) that could provide a positive barrier effect against migration and a controlled continual release of 0.25 microg/h extended to 9 days. Mechanical tests of @entity2701 , compression, and traction showed the crucial influence of the ring's hydration state. The cytocompatibility study showed no evidence of cellular @entity137 . DISCUSSION/CONCLUSIONS: The synthesized copolymer is able to release a constant, regular and safe rate of @entity1487 , higher than CI50 over a period of 9 days for a cell proliferation phase of 3-5 days. We adjusted the ring associating the mechanical properties and the ability to release @entity1487 , allowing further evaluation on animal models, the subject of the second part of this report.

[Non-biodegradable drug-sustained capsular ring for prevention of secondary XXXX . Part I: In vitro evaluation].

@entity2003 :: ('MESH:D009127', 'Disease') :: ['rigidity'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity2701 :: ('MESH:D018781', 'Disease') :: ['tension'] @entity5348 :: ('MESH:C032802', 'Chemical') :: ['HPMA'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity231 :: (MESH:D002386,Disease) :: ['cataract']
